IKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inhibikase Therapeutics Inc (IKT) does not present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks significant positive catalysts, has weak technical indicators, and shows financial challenges. A hold position is recommended until clearer growth signals emerge.
The MACD is negative and contracting, RSI is neutral at 20.285, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 1.81, with key support at 1.623 and resistance at 1.997.
Analysts have initiated coverage with buy ratings and price targets of $4 and $6, citing the potential of IKT-001 in pulmonary arterial hypertension and undervaluation of shares. The company improved its cash position significantly to $178.8 million as of December 31, 2025.
The company reported a GAAP EPS of -$0.49 for FY 2025, indicating profitability challenges. Research and development expenses and SG&A expenses have increased significantly, impacting profitability. Insider and hedge fund trading trends are neutral, and there is no recent congress trading data.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved slightly but remained negative at -$12.73 million. EPS dropped significantly by -86.67% YoY, reflecting worsening profitability. Cash position improved to $178.8 million, but operational expenses have risen sharply.
Analysts from Ladenburg and BofA have initiated buy ratings with price targets of $4 and $6, citing strong potential for IKT-001 in pulmonary arterial hypertension and undervaluation of shares. However, the stock's financial performance and profitability challenges may limit short-term growth.
